# Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency

> **NCT01312636** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 36 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Congenital FVII Deficiency

## Interventions

- **DRUG:** activated recombinant human factor VII

## Key facts

- **NCT ID:** NCT01312636
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2014-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01312636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01312636, "Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01312636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*